Back to All Resources

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition

December 12, 2022

American Society of Hematology Annual Meeting and Expo

Leveraging Pre-Clinical Animal Model - 2
View Poster
Area of Focus
Oncology
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

August 24, 2022
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
ACS Fall 2022
MYD88 Tumors
View Resource
June 26, 2022
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology
37th ACS National Medicinal Chemistry Symposium
MYD88 Tumors
View Resource
June 7, 2022
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
Targeting protein degradation 3 – from discovery to the clinic (TPD3)
MYD88 Tumors
View Resource